CIPOLLI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 2.126
EU - Europa 1.907
AS - Asia 1.491
SA - Sud America 221
AF - Africa 43
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.793
Nazione #
US - Stati Uniti d'America 2.074
RU - Federazione Russa 804
SG - Singapore 527
CN - Cina 468
GB - Regno Unito 374
IT - Italia 194
BR - Brasile 167
VN - Vietnam 165
HK - Hong Kong 109
SE - Svezia 99
DE - Germania 89
FR - Francia 87
IE - Irlanda 77
FI - Finlandia 72
KR - Corea 59
BD - Bangladesh 44
CA - Canada 31
IN - India 27
JP - Giappone 18
NL - Olanda 18
EC - Ecuador 17
ID - Indonesia 17
AR - Argentina 16
BE - Belgio 16
ES - Italia 16
MX - Messico 15
ZA - Sudafrica 15
PL - Polonia 13
UA - Ucraina 13
TR - Turchia 11
NG - Nigeria 9
AT - Austria 8
PK - Pakistan 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
IQ - Iraq 6
PY - Paraguay 6
BJ - Benin 5
CO - Colombia 5
AU - Australia 4
CH - Svizzera 4
LT - Lituania 4
MA - Marocco 4
CL - Cile 3
CZ - Repubblica Ceca 3
TG - Togo 3
BG - Bulgaria 2
BO - Bolivia 2
EG - Egitto 2
JM - Giamaica 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MD - Moldavia 2
OM - Oman 2
PE - Perù 2
UY - Uruguay 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PH - Filippine 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
VE - Venezuela 1
YT - Mayotte 1
Totale 5.793
Città #
Southend 303
Dallas 285
Moscow 275
Singapore 272
Ashburn 264
Chandler 248
San Jose 203
Beijing 109
Hong Kong 107
Woodbridge 91
Ann Arbor 87
Verona 85
Dublin 77
The Dalles 69
Jacksonville 58
New York 56
Council Bluffs 55
Ho Chi Minh City 50
Los Angeles 46
Houston 44
Helsinki 39
Hanoi 38
Nanjing 36
Munich 29
Lawrence 28
Princeton 28
Jinan 27
Buffalo 24
Shenyang 24
Seoul 23
Wilmington 22
Santa Clara 20
São Paulo 19
Tokyo 17
Milan 15
Brussels 14
Hebei 14
Amsterdam 13
Changsha 13
Montreal 12
Dong Ket 11
Jakarta 11
Johannesburg 11
London 11
Warsaw 11
Columbus 10
Denver 10
Redondo Beach 10
Taizhou 10
Turku 10
Abuja 9
Ankara 9
Bologna 9
Chennai 9
Nanchang 9
Ningbo 9
Stockholm 9
Boardman 8
Chicago 8
Frankfurt am Main 8
Haikou 8
Orem 8
Tianjin 8
Brooklyn 7
Sindelfingen 7
Tashkent 7
Zhengzhou 7
Falkenstein 6
Ferrara 6
Hangzhou 6
Jiaxing 6
Norwalk 6
Quito 6
San Francisco 6
Seattle 6
Vienna 6
Asunción 5
Atlanta 5
City of London 5
Cotonou 5
Falls Church 5
Guangzhou 5
Hải Dương 5
Lanzhou 5
Lappeenranta 5
Mexico City 5
Osasco 5
Redwood City 5
Rio de Janeiro 5
Rome 5
Taiyuan 5
Toronto 5
Washington 5
Auburn Hills 4
Baghdad 4
Boston 4
Guayaquil 4
Haiphong 4
Mumbai 4
Nuremberg 4
Totale 3.650
Nome #
International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. 283
A longitudinal study of glucose tolerance in cystic fibrosis: the central role of beta cell functional mass 204
Ataluren-driven Restoration of Shwachman-Bodian-Diamond Syndrome Protein Function in Shwachman-Diamond Syndrome Bone Marrow Cells 202
Further characterization of Shwachman-Diamond syndrome: psychological functioning and quality of life in adult and young patients. 191
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series 184
Further Insights into the Hematological Disorders Observed in Shwachman-Diamond Syndrome: mTOR and STAT3 Hyper-Phosphorylation in CD4+ and CD8+ T Cells and Efficacy of Rapamycin Treatment 182
Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. 179
Evaluation of energy metabolism and calcium homeostasis in cells affected by Shwachman-Diamond syndrome 173
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 172
Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. 169
291 Colon cancer screening program in adult CF patients: an Italian cross-sectional pilot study 167
Identification of novel mutations in patients with Shwachman-Diamond syndrome 166
Absence of acquired copy number neutral loss of heterozygosity (CN-LOH) of chromosome 7 in a series of 10 patients with Shwachman-Diamond syndrome 162
Real-Life Experience with CFTR Modulators Shows Correction of LAD-IV Phenotype in Cystic Fibrosis 159
Optical Measurements of Sweat for in Vivo Quantification of CFTR Function in Individual Sweat Glands 158
Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells 156
A Prospective Study of Hematologic Complications and Long-Term Survival of Italian Patients Affected by Shwachman-Diamond Syndrome 156
Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. 154
GENETIC ANALYSIS OF THE SBDS GENE AMONG NON-ITALIAN PATIENTS 150
A Prospective Haematological Survey Of Italian Patients Affected By Shwachman-Diamond Syndrome: Results Of A Ten Years Multicentric Study 150
Shwachman-Diamond syndrome 146
Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis 139
Constitutive systemic inflammation in Shwachman-Diamond Syndrome 138
Peripheral blood immunophenotyping in a large cohort of patients with Shwachman-Diamond syndrome 136
Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation 135
Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability 134
Celiac disease and obesity: need for nutritional follow-up after diagnosis. 133
Novel Translational Read-Through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome 130
SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation 129
Mutation Screening of Elongation Factor 2 in Shwachman-Diamond Syndrome Patients Lacking Mutations in the SBDS Gene 129
Normative growth charts for Shwachman-Diamond syndrome from Italian cohort of 0-8 years old 129
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 127
Efficacy of Elexacaftor–Tezacaftor–Ivacaftor on chronic rhinosinusitis in cystic fibrosis 116
Whole exome sequencing discloses heterozygous variants in the DNAJC21 and EFL1 genes but not in SRP54 in 6 out of 16 patients with Shwachman-Diamond Syndrome carrying biallelic SBDS mutations 114
New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes 113
Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia 97
Mesenchymal stromal cells from Shwachman-Diamond syndrome patients fail to recreate a bone marrow niche in vivo and exhibit impaired angiogenesis 92
Structural variation in SBDS gene, with loss of exon 3, in two Shwachman-Diamond patients 90
The Gluten Free Diet's Impact on Growth in Children with Celiac Disease in Two Different Countries 86
Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program 29
Totale 5.859
Categoria #
all - tutte 18.787
article - articoli 17.371
book - libri 0
conference - conferenze 1.416
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.574


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 0 0 0 0 0 0 27
2021/2022210 11 75 1 11 7 3 4 15 7 6 17 53
2022/2023587 32 81 42 113 48 134 4 32 68 8 15 10
2023/2024307 9 23 21 37 33 47 11 32 7 28 42 17
2024/2025852 34 30 36 164 36 33 44 32 150 38 71 184
2025/20262.911 146 155 314 510 685 176 252 153 209 167 64 80
Totale 5.859